Global Benign Prostatic Hyperplasia Treatment Market Growth, Size, Research Report and Forecast 2024-2032

Benign Prostatic Hyperplasia Treatment Market Size And Forecast

Benign Prostatic Hyperplasia Treatment Market size was valued at USD 9.24 Billion in 2023 and is projected to reach USD 15.65 Billion by 2030, growing at a CAGR of 6.81% during the forecast period 2024-2031.

The Benign Prostatic Hyperplasia (BPH) Treatment Market encompasses the pharmaceuticals, medical devices, and procedures aimed at managing and alleviating symptoms associated with benign prostatic hyperplasia. BPH, a prevalent condition among aging men, involves the enlargement of the prostate gland, leading to urinary tract symptoms such as urinary frequency, urgency, weak stream, and incomplete bladder emptying. The market includes a range of treatment options, from medication-based therapies to minimally invasive procedures and surgical interventions, catering to varying degrees of symptom severity and patient preferences.

Global Benign Prostatic Hyperplasia Treatment Market Drivers

The market drivers for the Benign Prostatic Hyperplasia Treatment Market can be influenced by various factors. These may include:

•  Population Aging: BPH is more common as people get older, especially in men over 50. The demand for treatment options is predicted to increase as the world’s population ages and the prevalence of BPH rises.
•  Growing Incidence of BPH: A number of variables, including dietary practices, environmental conditions, and lifestyle modifications, are contributing to the rising incidence of BPH globally. The increased recognition of BPH symptoms and the accessibility of efficacious therapies result in elevated rates of diagnosis and treatment-seeking behavior among afflicted parties.
•  Increasing Healthcare Expenditure: Access to healthcare services, such as BPH diagnosis and treatment, is made possible by rising healthcare spending, especially in emerging economies. Spending more on healthcare makes it easier for patients to receive cutting-edge treatments and enhances patient outcomes.
•  Technological Developments in Treatment Options: The creation of less intrusive and efficient BPH treatments has been made possible by developments in medical technology and surgical methods. The market is growing because cutting-edge techniques including prostatic artery embolization (PAE), transurethral microwave thermotherapy (TUMT), and laser therapy provide alternatives to conventional surgical procedures.
•  Patient Preference for Minimally Invasive Treatments: When compared to standard surgical procedures, patients choose minimally invasive treatment options that offer quicker recovery periods, a lower chance of problems, and an improved quality of life. Patients and medical professionals are increasingly favoring minimally invasive therapies for benign prostatic hyperplasia (BPH), including as transurethral resection of the prostate (TURP), holmium laser enucleation of the prostate (HoLEP), and prostate UroLift implants.
•  Increasing Awareness and Education activities: Patient and healthcare professional knowledge of BPH symptoms, risk factors, and available treatments is raised through healthcare awareness campaigns and educational activities. A greater understanding promotes prompt diagnosis and intervention, which increases demand for BPH treatment alternatives.
•  Frequency of Risk Factors Associated with Lifestyle: The onset and course of BPH are influenced by lifestyle-related risk factors, including obesity, a sedentary lifestyle, and poor eating habits. By addressing these risk factors through pharmacological therapies and lifestyle modifications, BPH symptoms can be managed and the disease’s progression can be delayed, which propels market growth.
•  Growing Need for Combination Therapies: For the treatment of BPH symptoms, doctors are increasingly prescribing combination therapies, which include many drugs with various modes of action. The market for BPH drugs is driven by combination therapies, which provide greater symptom alleviation and synergistic effects as compared to monotherapy.
•  Frequency of Comorbidities: BPH frequently coexists with other illnesses such diabetes, cardiovascular disease, and hypertension. Comorbidities increase the need for complete treatment solutions since they make managing BPH more difficult and necessitate a multidisciplinary approach involving urologists, primary care physicians, and other specialists.
•  Growing Geriatric Population: The prevalence of BPH and other age-related disorders is rising due in part to the aging population, especially in developed nations. The need for BPH treatment alternatives is anticipated to increase as the older population grows, propelling market expansion.

Global Benign Prostatic Hyperplasia Treatment Market Restraints

Several factors can act as restraints or challenges for the Benign Prostatic Hyperplasia Treatment Market. These may include:

•  Limited Effectiveness of Current Treatments: Although there are a number of BPH treatment choices, such as medication, surgery, and minimally invasive techniques, not all individuals may always respond well to them. Some patients may only receive a portion of their symptoms to be relieved, or they may need repeated interventions over time, which leaves them unhappy with their available treatment options.
•  Complications and Side Effects: A number of BPH treatments, including alpha-blockers, 5-alpha-reductase inhibitors, and surgery, may cause complications and side effects. Retrograde ejaculation, exhaustion, dizziness, and sexual dysfunction are common side effects. Some patients may choose not to pursue treatment or may decide to stop therapy altogether due to the possibility of problems.
•  Cost of Treatment: BPH patients may have high treatment costs, particularly if they do not have access to inexpensive healthcare services or sufficient insurance coverage. Some people’s access to treatment may be hampered by the cost of prescription drugs, medical procedures, and follow-up care, especially in areas with inadequate healthcare resources.
•  Preference for Conservative Management: Compared to pharmaceutical or surgical treatments, some patients with mild to moderate BPH symptoms may favor conservative management techniques such lifestyle changes, cautious waiting, or herbal remedies. The inclination towards non-invasive methods could perhaps decrease the need for medication or medical procedures.
•  Long-Term Safety and Efficacy Concerns: Patients and healthcare professionals may have concerns about the long-term safety and efficacy of BPH therapies, particularly medication and minimally invasive procedures. Limited information about long-term symptom improvement durability and possible side effects may influence therapy choices.
•  Patient Compliance and Adherence: Maintaining adherence to prescribed drug schedules and follow-up sessions is critical to getting the best possible results from BPH therapy. On the other hand, poor and non-adherence to treatment plans are frequent problems that result in inadequate symptom management and the advancement of the disease.
•  Stigma and Embarrassment: Patients’ quality of life may be negatively impacted by BPH symptoms, which include nocturia, urgency, and frequent urination. There may be delays in diagnosis and treatment beginning due to the stigma attached to talking about urine symptoms or seeking treatment for BPH.
•  Lack of Knowledge and Education: Many people may not be aware of the symptoms, risk factors, and potential treatments for BPH, especially those who live in rural or impoverished settings. Inadequate access to healthcare education and knowledge may be a factor in delayed diagnosis and inadequate BPH treatment.
•  Regulatory and Reimbursement Challenges: New BPH treatments may face difficulties finding a market if certain regulations and reimbursement practices are not followed. Innovative therapies may not be able to gain market acceptance if there are delays in regulatory approval, insurance provider coverage constraints, or reimbursement restrictions.
•  Demographic Trends: The prevalence of BPH is rising globally as a result of aging populations and longer life expectancies. However, aging populations and other demographic trends may put a pressure on healthcare systems and resources, making it more difficult to provide BPH treatment that is both timely and effective.

Global Benign Prostatic Hyperplasia Treatment Market Segmentation Analysis

The Global Benign Prostatic Hyperplasia Treatment Market is Segmented on the basis of Treatment Type, Drug Class, End-User, and Geography.

Benign Prostatic Hyperplasia Treatment Market, By Treatment Type

•  Medication: Segmentation based on pharmaceutical treatments for BPH, including alpha blockers (e.g., tamsulosin, alfuzosin) and 5-alpha reductase inhibitors (e.g., finasteride, dutasteride).
•  Minimally Invasive Procedures: Segmentation based on minimally invasive treatments for BPH, such as transurethral resection of the prostate (TURP), transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA), and laser therapy (e.g., photoselective vaporization of the prostate, holmium laser enucleation of the prostate).
•  Surgical Procedures: Segmentation based on surgical interventions for BPH, including open prostatectomy and minimally invasive surgeries like transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), and robotic-assisted prostatectomy.

Benign Prostatic Hyperplasia Treatment Market, By Drug Class

•  Alpha Blockers: Segmentation based on medications that relax the muscles in the prostate and bladder neck to improve urine flow and reduce BPH symptoms.
•  5-Alpha Reductase Inhibitors: Segmentation based on medications that shrink the prostate gland by blocking the production of dihydrotestosterone (DHT), a hormone responsible for prostate enlargement.
•  Combination Therapy: Segmentation based on medications that combine alpha blockers and 5-alpha reductase inhibitors to provide synergistic effects in managing BPH symptoms.
•  Phytotherapy: Segmentation based on herbal remedies and supplements used for managing BPH symptoms, such as saw palmetto, pygeum africanum, and stinging nettle.

Benign Prostatic Hyperplasia Treatment Market, By End-User

•  Hospitals: Segmentation based on BPH treatment services provided by hospitals, including diagnosis, medication management, and surgical interventions.
•  Ambulatory Surgical Centers (ASCs): Segmentation based on outpatient facilities that offer minimally invasive procedures and surgical treatments for BPH, providing convenience and shorter recovery times.
•  Specialty Clinics: Segmentation based on clinics specializing in urology and men’s health, offering comprehensive BPH management and personalized treatment plans.
•  Homecare Settings: Segmentation based on BPH treatments delivered at home, including medication management, self-care practices, and monitoring of symptoms under the supervision of healthcare professionals.

Benign Prostatic Hyperplasia Treatment Market, By Geography

•  North America: Market conditions and demand in the United States, Canada, and Mexico.
•  Europe: Analysis of the Benign Prostatic Hyperplasia Treatment Market in European countries.
•  Asia-Pacific: Focusing on countries like China, India, Japan, South Korea, and others.
•  Middle East and Africa: Examining market dynamics in the Middle East and African regions.
•  Latin America: Covering market trends and developments in countries across Latin America.

Key Players

The major players in the Benign Prostatic Hyperplasia Treatment Market are:

•  Abbott Laboratories
•  AbbVie (Allergan Plc)
•  Astellas Pharma Inc.
•  Boehringer Ingelheim GmbH & Co. KG
•  Eli Lilly and Company
•  GlaxoSmithKline plc.
•  Merck & Co., Inc. (Merck Sharp & Dohme Corp)
•  Pfizer Inc.
•  Sanofi
•  Teva Pharmaceutical Industries Ltd.
•  Boston Scientific Corporation
•  Teleflex Incorporated
•  Endo International plc
•  Urologix, LLC
•  LISA Laser Surgeries
•  Olympus Corporation

Report Scope

Analyst’s Take

The Benign Prostatic Hyperplasia Treatment Market is witnessing steady growth owing to several factors such as the aging population demographic, increasing awareness about prostate health, and advancements in medical technology. Pharmaceutical companies are developing innovative drugs with improved efficacy and safety profiles, while medical device manufacturers are introducing minimally invasive treatment options offering reduced recovery times and enhanced patient outcomes. Additionally, strategic collaborations between healthcare providers, research institutions, and industry players are fostering the development of personalized treatment approaches tailored to individual patient needs. As a result, the BPH treatment market is poised for further expansion in the coming years, presenting lucrative opportunities for stakeholders across the healthcare continuum.

Research Methodology of Market Research:

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

•  Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
•  Provision of market value (USD Billion) data for each segment and sub-segment
•  Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
•  Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
•  Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
•  Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
•  The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
•  Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
•  Provides insight into the market through Value Chain
•  Market dynamics scenario, along with growth opportunities of the market in the years to come
•  6-month post-sales analyst support

Customization of the Report

•  In case of any please connect with our sales team, who will ensure that your requirements are met.